Part 5 of our Deep GUNA Research series, for practitioners.
This article is written for a practitioner audience and draws directly on GUNA's own published research. It is educational in nature and does not replace clinical judgement or personalised medical advice. K2F-DIA and K2M-DIA are not substitutes for insulin, and any change to insulin therapy must only ever be made by the treating physician.
The third and final pair of INET medicines is the most specialised in the range. K2F-DIA (for women) and K2M-DIA (for men) are compounds used as adjuvants in the treatment of Type 1 (insulin-dependent) diabetes — built on the same neuroendocrine foundation as K2F and K2M, but adapted with the pancreatic loculus specifically in mind.
Full Composition
What Changes From the Basic Structure, and Why
At first glance, K2F-DIA and K2M-DIA carry across the familiar INET backbone, combined with the classic core of INET oligoelements — Zinc, Nickel and Cobalt — and the organotherapies Hepar suis, Cor suis and Pulmo suis. GUNA selected liver, heart and lung tissue here for their role in the energy regulation of the pancreatic loculus, following the law of the Five Energy Movements of Acupuncture as described by Nguyen Van Nghi.
Compared to K2F and K2M, two things are expanded specifically for this formula. Pancreas suis is given across three potencies (D6, D12 and 200K) rather than a single dilution, alongside Hepar suis, Cor suis and Pulmo suis at 200K. The oligoelement trio — Cobaltum gluconicum, Zincum gluconicum and Niccolum gluconicum, each at D6 — forms what GUNA describes as the classic core of INET trace-element support, added here for its relevance to pancreatic and metabolic function.
Posology
10 drops, 2-3 times a day. Do not exceed the maximum daily dose of 30 drops.
IMPORTANT NOTE: K2F-DIA and K2M-DIA are not substitutes for insulin.
Scope of Application and Insulin Therapy
GUNA's own literature is explicit that insulin therapy should continue in accordance with the usual procedure. It will be reduced appropriately, and only in accordance with any possible drop in glycaemic levels, as assessed by the treating physician. GUNA's stated scope of application for K2F-DIA and K2M-DIA is also narrower than for the rest of the INET range: it is limited specifically to cases of Type 1 diabetes where physiopathological conditions of recent and partial autoimmune damage have been confirmed, rather than diabetes in general.
The next and final article in this series covers GUNA's own published clinical case reports — including the case series that lies behind this tertiary group's development.
Featured products
Guna K2F DIA
Adjunct neuroendocrine support for women with Type 1 diabetes.
Explore the full Guna Endocrinology range — INET compounds and neuroendocrine support built on GUNA’s PNEI research.
Not sure which remedy is right for you?
Try our Natural Remedy Finder, or contact our team for guidance.
Related reading
- Senectus F and Senectus M in Full: Composition and Ingredient Rationale
- GUNA's Clinical Case Reports: Male Infertility and Type 1 Diabetes
- The Foundations of INET: From Homotoxicology to the Neuroendocrine-Immune Network
Source: GUNA, *From Homotoxicology to INET*, "The Tertiary Group of Medicines — K2F-DIA and K2M-DIA."
Tags: Deep Guna Research, Guna Articles, K2F-DIA, K2M-DIA, Diabetes Support